NOVARTIND
Novartis India Limited
Novartis India Limited (NOVARTIND) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
novartis.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Stock price
₹1897.60
Market cap
4,683 Cr
Stock P/E
47.9
P/B
5.73
Dividend yield
1.3%
ROE (FY26)
11.4%
ROCE (FY26)
16.0%
Operating margin (FY26)
26.0%
OCF / EBITDA (FY26)
49.7%
OCF / EBITDA (3Y)
93.6%
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Sells branded medicines in India to doctors and patients, from long-established pain, calcium, women's health, brain-health and transplant brands such as Voveran, Calcium Sandoz, Methergin and Myfortic.
Company snapshot
63rdBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
Positives
- ✓Net margin of 26.3% — the business keeps a healthy share of every rupee it earns.
3 more signals from the filings.Sign in free to see them all
Statement tables · Standalone
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Standalone only
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 Cr | 85 Cr | 81 Cr | 92 Cr | 87 Cr | 93 Cr | 84 Cr | 88 Cr | 90 Cr | 86 Cr | 91 Cr | 104 Cr |
| Operating expenses (approx.) | 62 Cr | 65 Cr | 70 Cr | 68 Cr | 69 Cr | 67 Cr | 60 Cr | 60 Cr | 66 Cr | 64 Cr | 70 Cr | 69 Cr |
| EBITDA | 17 Cr | 20 Cr | 11 Cr | 24 Cr | 18 Cr | 26 Cr | 24 Cr | 27 Cr | 24 Cr | 22 Cr | 21 Cr | 35 Cr |
| OPM % | 21.5% | 23.4% | 13.8% | 26.0% | 20.6% | 27.5% | 28.5% | 31.1% | 26.4% | 26.0% | 22.8% | 33.6% |
| Other income | 17 Cr | 22 Cr | 10 Cr | 10 Cr | 10 Cr | 11 Cr | 11 Cr | 11 Cr | 9 Cr | 9 Cr | 10 Cr | 9 Cr |
| Interest | 0.71 Cr | 0.16 Cr | 0.16 Cr | 0.15 Cr | 0.14 Cr | 0.36 Cr | 0.12 Cr | 0.10 Cr | 0.11 Cr | 0.98 Cr | 0.07 Cr | 0.06 Cr |
| Depreciation | 0.65 Cr | 0.26 Cr | 0.14 Cr | 0.55 Cr | 0.58 Cr | 0.53 Cr | 0.53 Cr | 0.53 Cr | 0.52 Cr | 0.48 Cr | 0.42 Cr | 0.42 Cr |
| Profit before tax | 32 Cr | 41 Cr | 21 Cr | 34 Cr | 28 Cr | 35 Cr | 34 Cr | 37 Cr | 33 Cr | 30 Cr | 30 Cr | 43 Cr |
| Tax % | 27.0% | 35.7% | 31.2% | 23.6% | 25.9% | 27.9% | 13.5% | 25.8% | 25.8% | 45.7% | 16.2% | 25.4% |
| Net profit | 24 Cr | 27 Cr | 15 Cr | 26 Cr | 20 Cr | 25 Cr | 29 Cr | 28 Cr | 24 Cr | 16 Cr | 25 Cr | 32 Cr |
| EPS (₹) | ₹9.59 | ₹10.76 | ₹5.95 | ₹10.42 | ₹8.27 | ₹10.31 | ₹11.87 | ₹11.19 | ₹9.81 | ₹6.52 | ₹10.23 | ₹13.05 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 656 Cr | 564 Cr | 491 Cr | 438 Cr | 381 Cr | 400 Cr | 379 Cr | 335 Cr | 356 Cr | 354 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 631 Cr | 570 Cr | 478 Cr | 426 Cr | 355 Cr | 373 Cr | 314 Cr | 270 Cr | 265 Cr | 260 Cr | Sign in free for the trailing twelve months |
| EBITDA | 25 Cr | -6 Cr | 12 Cr | 12 Cr | 27 Cr | 27 Cr | 65 Cr | 65 Cr | 91 Cr | 94 Cr | Sign in free for the trailing twelve months |
| OPM % | 3.8% | -1.1% | 2.5% | 2.7% | 7.0% | 6.8% | 17.2% | 19.5% | 25.7% | 26.6% | Sign in free for the trailing twelve months |
| Other income | 71 Cr | 172 Cr | 78 Cr | 36 Cr | 33 Cr | 33 Cr | 58 Cr | 62 Cr | 42 Cr | 39 Cr | Sign in free for the trailing twelve months |
| Interest | 0.72 Cr | 6 Cr | 2 Cr | 6 Cr | 8 Cr | 5 Cr | 2 Cr | 1 Cr | 0.77 Cr | 1 Cr | Sign in free for the trailing twelve months |
| Depreciation | 4 Cr | 3 Cr | 3 Cr | 13 Cr | 12 Cr | 10 Cr | 6 Cr | 3 Cr | 2 Cr | 2 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 92 Cr | 158 Cr | 86 Cr | 29 Cr | 40 Cr | -4 Cr | 115 Cr | 123 Cr | 130 Cr | 130 Cr | Sign in free for the trailing twelve months |
| Tax % | 37.6% | 50.3% | 39.6% | 64.8% | 47.8% | 2.6% | 10.4% | 30.6% | 22.6% | 28.1% | Sign in free for the trailing twelve months |
| Net profit | 57 Cr | 78 Cr | 52 Cr | 10 Cr | 21 Cr | -4 Cr | 103 Cr | 85 Cr | 101 Cr | 93 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹19.10 | ₹28.43 | ₹20.97 | ₹4.08 | ₹8.46 | ₹-1.51 | ₹41.86 | ₹34.50 | ₹40.87 | ₹37.74 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | 118.1% | — | 23.9% | 137.7% | 61.2% | 66.2% | Sign in free for the trailing twelve months |
Sign in free for the trailing twelve months
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr | 12 Cr |
| Reserves | 906 Cr | 721 Cr | 747 Cr | 708 Cr | 699 Cr | 679 Cr | 763 Cr | 732 Cr | 773 Cr | 805 Cr |
| Borrowings | — | — | — | — | — | — | — | 0.02 Cr | — | — |
| Other liabilities | 230 Cr | 377 Cr | 223 Cr | 357 Cr | 291 Cr | 266 Cr | 207 Cr | 180 Cr | 163 Cr | 160 Cr |
| Total liabilities | 1,150 Cr | 1,111 Cr | 982 Cr | 1,078 Cr | 1,002 Cr | 958 Cr | 983 Cr | 925 Cr | 948 Cr | 978 Cr |
| Fixed assets (net) | 6 Cr | 5 Cr | 15 Cr | 76 Cr | 64 Cr | 24 Cr | 19 Cr | 7 Cr | 5 Cr | 3 Cr |
| CWIP | 0.01 Cr | — | — | — | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | — |
| Investments | — | — | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Loans & advances | — | — | 0.06 Cr | 0.06 Cr | 0.06 Cr | 0.46 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Inventories | 88 Cr | 57 Cr | 61 Cr | 59 Cr | 48 Cr | 57 Cr | 55 Cr | 45 Cr | 41 Cr | 53 Cr |
| Trade receivables | 41 Cr | 44 Cr | 46 Cr | 38 Cr | 39 Cr | 45 Cr | 36 Cr | 41 Cr | 40 Cr | 37 Cr |
| Cash & bank | 76 Cr | 38 Cr | 88 Cr | 79 Cr | 68 Cr | 158 Cr | 19 Cr | 45 Cr | 52 Cr | 53 Cr |
| Other assets | 940 Cr | 968 Cr | 774 Cr | 826 Cr | 783 Cr | 673 Cr | 853 Cr | 787 Cr | 810 Cr | 833 Cr |
| Total assets | 1,150 Cr | 1,111 Cr | 982 Cr | 1,078 Cr | 1,002 Cr | 958 Cr | 983 Cr | 925 Cr | 948 Cr | 978 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | -41 Cr | 161 Cr | -194 Cr | -23 Cr | -69 Cr | 39 Cr | 45 Cr | 113 Cr | 75 Cr | 47 Cr |
| Cash from investing | 424 Cr | 69 Cr | 274 Cr | 56 Cr | 95 Cr | 87 Cr | -153 Cr | 33 Cr | -3 Cr | 18 Cr |
| Cash from financing | -332 Cr | -268 Cr | -30 Cr | -41 Cr | -37 Cr | -36 Cr | -30 Cr | -121 Cr | -64 Cr | -64 Cr |
| Net cash flow | 51 Cr | -38 Cr | 50 Cr | -9 Cr | -11 Cr | 90 Cr | -139 Cr | 26 Cr | 7 Cr | 0.43 Cr |
| Free cash flow (OCF − Capex) | -44 Cr | 160 Cr | -208 Cr | -24 Cr | -69 Cr | 38 Cr | 44 Cr | 113 Cr | 75 Cr | 46 Cr |
Ratios
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 10.1% | 22.2% | 11.5% | 4.9% | 6.7% | 0.1% | 15.1% | 16.7% | 16.7% | 16.0% |
| ROE % | 6.2% | 10.7% | 6.8% | 1.4% | 2.9% | -0.5% | 13.3% | 11.4% | 12.9% | 11.4% |
| Debtor days | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 | 38 |
| Inventory days | 265477 | 37 | 45 | 49 | 46 | 52 | 53 | 49 | 42 | 55 |
| Days payable | 222101 | 68 | 68 | 60 | 53 | 66 | 57 | 67 | 53 | 56 |
| Cash conversion cycle | 43399 | -4 | 11 | 20 | 30 | 27 | 30 | 27 | 30 | 37 |
| OCF / EBITDA % | -163.1% | — | n.m. | n.m. | -258.3% | 142.6% | 68.8% | 173.8% | 81.6% | 49.7% |
| OCF / EBITDA % (3 years) | — | — | n.m. | n.m. | -560.9% | -81.4% | 12.0% | 125.0% | 105.0% | 93.6% |
| Debt / equity | — | — | — | — | — | — | 0.00 | 0.0000 | — | — |
| Current ratio | 5.32 | 2.89 | 4.35 | 3.49 | 4.55 | 3.27 | 4.25 | 4.45 | 5.25 | 5.30 |
| Net debt / EBITDA | -3.02 | — | -7.15 | -6.58 | -2.55 | -5.84 | -0.30 | -0.69 | -0.57 | -0.56 |